<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="37922">Arbekacin</z:chebi> (ABK) was administered to 17 patients with <z:e sem="disease" ids="C0343401" disease_type="Disease or Syndrome" abbrv="">MRSA infections</z:e> that complicated underlying hematopoietic disorders, and the efficacy and safety were evaluated </plain></SENT>
<SENT sid="1" pm="."><plain>The underlying diseases included <z:hpo ids='HP_0004808'>acute myelocytic leukemia</z:hpo> (8 cases), <z:hpo ids='HP_0011009'>acute</z:hpo> lymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (1) <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (3), <z:hpo ids='HP_0011010'>chronic</z:hpo> myelocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (1), non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (2), <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e> (1) and adult T cell <z:hpo ids='HP_0001909'>leukemia</z:hpo> (1) </plain></SENT>
<SENT sid="2" pm="."><plain>The <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> consisted of <z:mpath ids='MPATH_681'>septicemia</z:mpath> (5 cases), <z:hpo ids='HP_0002090'>pneumonia</z:hpo> (4), <z:hpo ids='HP_0002788'>upper respiratory tract infections</z:hpo> (6) and <z:hpo ids='HP_0000010'>urinary tract infections</z:hpo> (2) </plain></SENT>
<SENT sid="3" pm="."><plain>ABK was administered by i.v. drip infusion in daily doses of 150-200 mg, given in two divided dosages </plain></SENT>
<SENT sid="4" pm="."><plain>The therapeutic efficacies were: excellent in 2 (2 <z:mpath ids='MPATH_681'>septicemias</z:mpath>), good in 7 (1 <z:mpath ids='MPATH_681'>septicemia</z:mpath>, 4 upper <z:hpo ids='HP_0011947'>respiratory infections</z:hpo>, 2 <z:hpo ids='HP_0000010'>urinary tract infections</z:hpo>), fair in 2 (<z:mpath ids='MPATH_681'>septicemia</z:mpath> and <z:hpo ids='HP_0002090'>pneumonia</z:hpo>) and poor in 6 (1 <z:mpath ids='MPATH_681'>septicemia</z:mpath>, 3 <z:hpo ids='HP_0002090'>pneumonias</z:hpo>, 2 upper <z:hpo ids='HP_0011947'>respiratory infections</z:hpo>) </plain></SENT>
<SENT sid="5" pm="."><plain>As a side effect, reversible <z:hpo ids='HP_0000082'>renal dysfunction</z:hpo> was detected in four cases </plain></SENT>
<SENT sid="6" pm="."><plain>Causative bacteria were isolated from six cases </plain></SENT>
<SENT sid="7" pm="."><plain>They were <z:hpo ids='HP_0000001'>all</z:hpo> coagulase type II and MIC's of ABK were from 0.25 microgram/ml to 4.0 micrograms/ml </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="37922">Arbekacin</z:chebi> therapy was found to be effective even in patients with hematopoietic disorders accompanied by <z:e sem="disease" ids="C0343401" disease_type="Disease or Syndrome" abbrv="">MRSA infections</z:e> </plain></SENT>
</text></document>